996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14
Frank Lin(The University of Sydney), D. Thomas(UNSW Sydney), M. Itchins(Royal North Shore Hospital), Rosemary Harrup(University of Tasmania), Harpreet S. Takhar(Kaiser Permanente), Michelle M. Cummins(The University of Sydney), A. Mersiades(The University of Sydney), B.J. Solomon(Peter MacCallum Cancer Centre), Subotheni Thavaneswaran(The University of Sydney), J. Desai(Peter MacCallum Cancer Centre), Adnan Nagrial(Westmead Hospital), S. Chinchen(The University of Sydney), Chee Khoon Lee(The University of Sydney), M. Aberoumand(The University of Sydney), W. Xu(Princess Alexandra Hospital), John Simes(The University of Sydney), M. Kansara(UNSW Sydney), Sonia Yip(The University of Sydney), David Espinoza(The University of Sydney), N. Pavlakis(Royal North Shore Hospital)
Cited by 0
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Interpretation of the evidence for the efficacy and safety of statin therapy
|The Lancet|2016|1.8k
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
|Journal of Thoracic Oncology|2016|842
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695